NOVO NORDISK A/S-B (NOV.DE) Stock Price, Quote, News and Overview
FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR
NOV.DE Quote, Performance and Key Statistics
FRA:NOV (4/25/2025, 5:29:52 PM)
54.3
-0.66 (-1.2%)
The current stock price of NOV.DE is 54.3 EUR. In the past month the price decreased by -20.29%. In the past year, price decreased by -53.86%.
NOV.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 66.9 | 724.93B | ||
| 1LLY.MI | ELI LILLY & CO | 65.4 | 708.62B | ||
| ZEG.DE | ASTRAZENECA PLC | 16.94 | 379.17B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.31 | 325.76B | ||
| SNW.DE | SANOFI | 12.15 | 228.48B | ||
| SAN.PA | SANOFI | 13.72 | 226.10B | ||
| 6MK.DE | MERCK & CO. INC. | 10.36 | 175.14B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.16 | 171.87B | ||
| PFE.DE | PFIZER INC | 7.37 | 114.17B | ||
| 1PFE.MI | PFIZER INC | 7.17 | 111.02B | ||
| BRM.DE | BRISTOL-MYERS SQUIBB CO | 41.69 | 84.82B | ||
| ZOE.DE | ZOETIS INC | 25.71 | 59.64B |
Related stock screener links
About NOV.DE
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO NORDISK A/S-B
Novo Alle 1
Bagsvaerd DK
Employees: 69260
Company Website: https://www.novonordisk.com/
Investor Relations: https://www.novonordisk.com/investors.html
Phone: 4544448888
NOVO NORDISK A/S-B / NOV.DE FAQ
What is the stock price of NOVO NORDISK A/S-B today?
The current stock price of NOV.DE is 54.3 EUR. The price decreased by -1.2% in the last trading session.
What is the ticker symbol for NOVO NORDISK A/S-B stock?
The exchange symbol of NOVO NORDISK A/S-B is NOV and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is NOV.DE stock listed?
NOV.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for NOVO NORDISK A/S-B stock?
32 analysts have analysed NOV.DE and the average price target is 108.61 EUR. This implies a price increase of 100.02% is expected in the next year compared to the current price of 54.3. Check the NOVO NORDISK A/S-B stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVO NORDISK A/S-B worth?
NOVO NORDISK A/S-B (NOV.DE) has a market capitalization of 241.04B EUR. This makes NOV.DE a Mega Cap stock.
How many employees does NOVO NORDISK A/S-B have?
NOVO NORDISK A/S-B (NOV.DE) currently has 69260 employees.
What are the support and resistance levels for NOVO NORDISK A/S-B (NOV.DE) stock?
NOVO NORDISK A/S-B (NOV.DE) has a resistance level at 58.6. Check the full technical report for a detailed analysis of NOV.DE support and resistance levels.
Is NOVO NORDISK A/S-B (NOV.DE) expected to grow?
The Revenue of NOVO NORDISK A/S-B (NOV.DE) is expected to grow by 23.4% in the next year. Check the estimates tab for more information on the NOV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVO NORDISK A/S-B (NOV.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NOV.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NOV.DE, evaluating the profitability, health, valuation and growth aspects
- NOVO NORDISK A/S-B (NOV.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVO NORDISK A/S-B (NOV.DE) Sales and EPS estimates to see what analysts future expectations are.
- NOVO NORDISK A/S-B (NOV.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVO NORDISK A/S-B (NOV.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVO NORDISK A/S-B (NOV.DE) Stock Chart to make your own analysis
- NOVO NORDISK A/S-B (NOV.DE) Latest news and press-releases to stay up to date.
Does NOVO NORDISK A/S-B (NOV.DE) stock pay dividends?
NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 2.71%. The yearly dividend amount is currently 1.33. Check the full fundamental report for a detailed analysis of NOV.DE dividend history, reliability and sustainability.
When does NOVO NORDISK A/S-B (NOV.DE) report earnings?
NOVO NORDISK A/S-B (NOV.DE) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of NOVO NORDISK A/S-B (NOV.DE)?
The PE ratio for NOVO NORDISK A/S-B (NOV.DE) is 17.92. This is based on the reported non-GAAP earnings per share of 3.03 and the current share price of 54.3 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NOV.DE.
NOV.DE Technical Analysis
NOV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. NOV.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
NOV.DE Financial Highlights
Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.03. The EPS increased by 21.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.78% | ||
| ROA | 21.68% | ||
| ROE | 70.38% | ||
| Debt/Equity | 0.62 |
NOV.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to NOV.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 23.4% for NOV.DE